Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) Income from Continuing Operations (2021 - 2025)

Medicinova (MNOV) has disclosed Income from Continuing Operations for 8 consecutive years, with 3768301.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations changed N/A to 3768301.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12956985.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 12010778.0 for FY2025, 8.7% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 3768301.0 at Medicinova, down from 3040148.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 6826044.0 in Q4 2021, with the low at 4275175.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 2301573.17, with a median of 2863840.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations plummeted 1945.77% in 2022, then soared 80.54% in 2023.
  • Over 5 years, Income from Continuing Operations stood at 6826044.0 in 2021, then tumbled by 153.38% to 3643712.0 in 2022, then soared by 43.63% to 2053839.0 in 2023, then crashed by 39.31% to 2861281.0 in 2024, then tumbled by 31.7% to 3768301.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 3768301.0, 3040148.0, and 3282137.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.